Tolerance of Intra-articular Injection Autologous Stromal Vascular Fraction for the Treatment of Rhizarthrosis

NCT05708430 | Recruiting Phase 2 DMC

• 1 other identifier: 2018/0419/HP
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 3

Brief Summary

Rhizarthosis is a common disease in the population (15%). It has a major impact on the function of the hand since it compromises the pollicidigitales claws and all gripping functions with the thumb. However, no curative medical treatment exists to date. The treatment is initially based on a symptomatic approach: analgesics, non-steroidal anti-inflammatories, immobilization orthoses or even intra-articular injections of corticosteroids or hyaluronic acid. When it is exceeded, surgical treatment is considered. This is also not a curative treatment. Indeed, the 3 types of main interventions proposed (arthrodesis, arthroplasty or trapezectomy) each have significant consequences for the patient: stiffness for the arthrodesis, risk of dislocation or failure of the material for the prosthesis, long consequences for the trapezectomy. , or potential complications of surgery. Stem cell-based therapies, in particular cells of the stromal vascular fraction derived from adipose tissue (FVS), are promising in various indications, including osteoarthritis of the knee. Autologous FVS is readily accessible by standard liposuction, with FVS isolated from adipose tissue by centrifugation. A safe and well-tolerated source of cells with angiogenic, anti-inflammatory, immunomodulatory and regenerative properties, its safety has been demonstrated in particular during phase 1 trials. Our objective is to assess the tolerance of an injection of FVS into the trapezio-metacarpal joint, when standard medical treatment has failed, and the rhizarthrosis has become painful enough to be eligible for surgery. Due to its immunomodulatory and cartilage regeneration properties, this injection would be performed to offer a less invasive and possibly curative treatment instead of surgery.

Conditions

Rhizarthrosis

Outcome Measures

Primary Outcomes (1)

• The primary endpoint is the number of treatment-attributable Grade ≥ 3 adverse reactions occurring over a 6-month period after intra-articular injection of FVS.

  The primary endpoint is the number of treatment-attributable Grade ≥ 3 adverse reactions occurring over a 6-month period after intra-articular injection of FVS.

  6 months

Study Arms (1)

FVS injection

EXPERIMENTAL

Intra-articular injection of autologous cells from the stromal vascular fraction derived from adipose tissue

Drug: SVF injection into wrist

Interventions

SVF injection into wrist DRUG

Intra-articular injection of autologous cells from the stromal vascular fraction derived from adipose tissue

FVS injection

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Rhizarthrosis DELL stage 1 to 3
• Symptomatic medical treatment for a period of at least 6 months (analgesic, orthosis, anti-inflammatory, etc. or intra-articular infiltration of the trapezio-metacarpal joint) which has become ineffective (surgical stage)
• EVA pain ≥ 4
• Quick Dash or PRWHE ≥ 20/100
• Affiliation to a social security scheme
• Person who has read and understood the information letter and signed the consent form

You may not qualify if:

• History of intra-articular injection of the trapezio-metacarpal (corticoid or hyaluronic acid) in the last 6 months
• Body Mass Index \< 18 kg/m2
• Contraindication to general or local anesthetics including XYLOCAINE 10 mg/mL ADRENALINE 0.005 mg/mL, solution for injection
• Contraindication to sedation or general anesthesia (left to the discretion of the anesthesiologist)
• Contraindication to liposuction (eg bleeding disorder)
• Documented severe allergy to conventional antibiotics such as β-lactams, cyclins, macrolides, quinolones, aminoglycosides, etc…
• Known hypersensitivity to human albumin or to any of the excipients (VIALEBEX 200 g/L, solution for infusion)
• A general or local infection near the sampling or injection sites
• Any surgery scheduled over the duration of the study of the hand (carpal tunnel type operation) or upper limb that may have an impact on the assessment of pain and/or functional indices
• Congenital or acquired immune deficiency
• Persons infected with HIV, HCV, HBV, HTLV and syphilis
• Contraindication to MRI, (eg, due to presence of pacemakers or other incompatible foreign material or claustrophobia)
• Contraindication to the injection of gadolinated contrast product (gadolinium) for performing MRI (history of hypersensitivity to gadolinated contrast products)
• Active COVID-19 infection (PCR positive)
• Any cardiovascular, metabolic, endocrine, psychiatric or cancerous pathology in uncontrolled evolution

Sponsors & Collaborators

• University Hospital, Rouen: lead

Study Sites (3)

Chu Amiens

Amiens, 80054, France

RECRUITING

CHU CAEN

Caen, 14033, France

RECRUITING

Chu Rouen

Rouen, 76031, France

RECRUITING

Central Study Contacts

Coquerel Dorothée

CONTACT

0232885365; Dorothee.Coquerel@chu-rouen.fr

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 23, 2023
• First Posted: February 1, 2023
• Study Start: February 15, 2024
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: February 17, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

FR (3)